Lorcaserin
Cases of skin cancer set to reach 263,000 in 2035 according to new report
The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe
Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved
The real-world findings support the long-term benefits of continuous treatment
Lilly commits additional $4.5bn for US manufacturing sites
The company has also opened its first dedicated genetic medicine facility in Indiana in the US
Potential US-Iran peace deal to redraw market winners and losers
With a 10-day ceasefire between Israel and Lebanon in effect, oil prices are retreating from recent highs
Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term
The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark
Novo Nordisk and Vivtex partner in deal worth up to $2.1bn
The companies aim to develop next-generation oral medicines for obesity and diabetes
AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies
Almost three billion people globally are thought to be either overweight or obese
Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s
Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients
Novo Nordisk’s Wegovy higher dose injection approved by UK MHRA for obesity
Obesity affects approximately 15 million people in the UK
Eisai submits new drug application for subcutaneous Leqembi in Japan
LEQEMBI is a treatment for early Alzheimer’s disease
Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025
As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...
Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment
The MHRA approval for IV dosing comes following positive results from the global phase 3 trial